For more than two decades, the Applied Pharmaceutical Analysis (APA) Conference has served as a leading industry forum for advancing analytical science in drug discovery and development.
APA connects scientists across pharma, biotech, CROs, academia, and regulatory agencies to share technologies, case studies, and solutions that support the development of new therapies.
21st Applied Pharmaceutical Analysis (APA) Conference
September 14-15-16, 2026
Sanofi, Cambridge
 |
Plenary Speaker Chongwoo Yu, PhD DCEP/OCP/OTS/CDER @ US Food and Drug Administration Challenges and Opportunities in Biomarker Bioanalysis
|
 |
Plenary Speaker Dr. Lei Xie, PhD Prof. Pharmaceutical Sciences @ Northeastern University, Bouve College of Health Sciences Harnessing AI for Bridging Translational Gaps In Drug Discovery
|
|
 |
Plenary Speaker Prof. Edward J. Kelly, PhD, ATS Member, Kidney Research Institute, Univ. of Washington, Department of Pharmaceutics Applications of Complex In Vitro Models of the Kidney and Intestine in Modeling Drug Disposition |
 |
Sean Kassim, PhD Director, OSIS, CDER, US Food and Drug Administration Oversight of Bioavailability and Bioequivalence Studies In Support of New and Generic Drugs and Therapeutic Biologics |
|
 |
Heather Myler, PhD Senior Director, Head of Immunogenicity & New Modalities @ Takeda The degree of validation needed for quantitative decision-making biomarkers vs more exploartory biomarkers - title TBA |
 |
Ronald R. Bowsher, PhD, FAAPS Partner & CSO @ B2S Life Sciences Insights Into Immunogenicity Testing of Contemporary Peptide Therapeutics |
|
 |
Jenny Valentine, PhD Senior Principal Scientist @ Regeneron A Streamlined Approach to Immunogenicity Assessment: From Analysis to Submission |
 |
Jason DelCarpini, PhD Director, Bioanalysis & Molecular Assays @ Moderna Real-world applications of AI in BA for small and large molecules - title TBA |
|
 |
Sarah Bean, PhD Senior Director Laboratory Sciences @ Charles River Laboratories |
 |
Jeongsup Shim, PhD Senior Principal Scientist @ Genentech Simplifying PK and Biomarker Analysis: High-Sensitivity Single-Dilution Assays With The NULISA Platform |
|
 |
Joshua Powers, PhD Senior Scientist @ BMS Emerging Hybrid LC-HRMS Assays for In Vivo DAR Shift Bioanalysis of ADCs |
 |
PJ Devine, PhD Scientific Director @ Bristol Myers Squibb Pharmaceutical Industry Perspectives On the Hype Vs Opportunities for New Approach Methodologies (NAMs) in Drug Discovery and Development |
|
 |
Matthew Cerny, PhD Senior Principal Scientist @ Pfizer Talk title TBA |
 |
Min Meng, PhD Chief Operations Officer, President of Resolian Talk title TBA |
|
 |
Amanda Hays, PhD Scientific Officer @ Bioagilytix qPCR & dPCR for GT bioanalysis in the non-clinical space - talk title TBA |
 |
Long Yuan, PhD Director, Head of Bioanalytical Group @ Biogen Quantitative Bioanalysis of Antibody-Oligonucleotide Conjugate |
|
 |
Zachary Parsons, PhD Principal Scientist @ Bristol Myers Squib Ex Vivo Biotransformations Masquerading As Bioanalytical Method Anomalies |
 |
Michael McCoy, PhD Associate Director, In Silico ADME, DMPK & Modeling @ Takeda Mind the Gap: In Silicon ADME as a New Approach Methodology for Human Prediction |
|
 |
Christine Bowman, PhD Principal Scientist @ Genentech Pralsetinib (tyrosin kinase inhibitor) - CYP3A4 anomaly - talk title TBA |
 |
Guangnong (Sunny) Zhang, PhD Director of Bioanalytical Chemistry @ Novo Nordisk Bioanalytical & Translational Considerations for Therapeutic siRNA and ASOs: Industry Practices, and IQ Consortium Recommendations |
|
 |
Zhican Wang, PhD Executive Director, Head of DMPK @ Revolution Medicines ADME and PKPD Consideration in the Discovery of RAS(ON) Tri-Complex Inhibitors: Daraxonrasib and Elironrasib as examples |
 |
Ryota Kikuchi, PhD Research Fellow @ AbbVie Allometric Scaling As a Viable and Practical Approach For Peptide PK Prediction |
|
APA 2026 Conference
The program will feature three focused workshops reflecting key areas of pharmaceutical analysis:
-
Regulated Bioanalysis – addressing regulatory perspectives, emerging technologies, immunogenicity and ADA assessment, and the use of AI/ML in regulated bioanalysis and documentation.
-
Discovery Bioanalysis & New Technologies – covering bioanalysis for oligonucleotides and antibody-conjugated oligos, complex and emerging modalities, biomarkers and multi-omics, and case studies on novel analytical platforms.
-
Mechanistic ADME – exploring new methodologies for drug metabolism and toxicity assessment, metabolite analysis and alternative models, analytical strategies for new modalities, and approaches for dose and exposure prediction.
Together, these workshops bring leading scientists from across the pharmaceutical ecosystem to discuss current scientific challenges, share innovative technologies, and advance analytical approaches that support the development of new therapies.
2026 Regulated Bioanalysis Workshop
Session I: Regulatory & Agency Perspectives
Session II: Emerging Technologies in Bioanalysis & Next Generation Modalities
Session III: Immunogenicity & ADA in Regulated Context
Session IV: AI/ML in Regulated Bioanalysis
2026 Discovery Bioanalysis and New Technologies Workshop
Session I: Discovery BA for Oligonucleotide Therapeutics & Antibody-Conjugated Platforms
Session II: Discovery BA for Complex & Emerging Therapeutic Modalities
Session III: Biomarkers & Multi-Omics in Discovery
Session IV: Case Studies on Novel Technologies & Implementation
2026 Mechanistic ADME Workshop
Session I: New Approach Methodology for Drug Metabolism & Toxicity
Session II: Mechanistic Insights Into Drug Metabolism, Human Metabolites, and Predictive Models
Session III: Mechanistic ADME of Emerging Therapeutic Modalities
Session IV: Mechanistic ADME for Dose and Exposure Prediction
DOWNLOAD 2025 APA PROGRAM GUIDE
The Applied Pharmaceutical Analysis (APA) Conference, now in its 21st year, is a scientific forum dedicated to advancing analytical science in support of drug discovery and drug development. Organized by The Boston Society, a non-profit scientific organization, APA brings together scientists from pharmaceutical companies, biotechnology firms, CROs, academia, and regulatory agencies to exchange knowledge, discuss emerging technologies, and address real-world challenges in pharmaceutical analysis.
Hosted in Cambridge, Massachusetts—one of the world’s leading biotechnology hubs—APA provides a focused, industry-driven meeting organized by scientists for scientists. The conference promotes practical solutions, cross-disciplinary collaboration, and education for both experienced professionals and the next generation of pharmaceutical scientists.
Join our Linkedin Group:
